Cormedix Inc. (CRMD)
NASDAQ:CRMD
Want to see CRMD full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.24Last Year’s EPS
0.29Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum: large Q1 revenue and adjusted EBITDA beats, raised full‑year guidance, successful REZZAYO Phase III top‑line results with near‑term regulatory path, and solid cash generation. Offsetting risks include near‑term reimbursement variability from TDAPA expiry affecting H2 2026, a nonrecurring $9M revenue adjustment, mark‑to‑market charges, and a delayed TPN Phase III timeline pushing that program into 2028. On balance the positive execution, guidance increases, pipeline progress (REZZAYO) and strong balance sheet outweigh the highlighted challenges.Company Guidance
Strong Revenue and EBITDA Beat
Q1 2026 net revenue $127.4M vs $39.1M in Q1 2025 (up ~226%), driven by DefenCath ($97.5M) and Melinta portfolio ($29.9M). Adjusted EBITDA $70M vs $23.6M (up ~197%), demonstrating significant margin expansion and core operating strength.
Raised Full-Year Guidance
Company raised FY2026 net revenue guidance from $300–320M to $325–345M (midpoint +~8%), adjusted EBITDA guidance from $100–125M to $115–135M (midpoint +~11%), and DefenCath revenue guidance from $150–170M to $175–195M (midpoint +~15.6%).
DefenCath Strong Utilization and Customer Adoption
Q1 DefenCath sales $97.5M; management reports durable utilization growth and increased customer run rates (utilization uptick Q4→Q1). Key large customers (U.S. Renal Care, IRC, Fresenius) published/announced positive real-world results, supporting clinical adoption.
REZZAYO Phase III (ReSPECT) Top-Line Success
ReSPECT met primary endpoint: fungal‑free survival at day 90 60.7% (REZZAYO) vs 59.0% (standard), demonstrating non-inferiority across Candida, Aspergillus and Nosocomial pathogens and favorable secondary safety endpoints (fewer TEAEs leading to dose changes/withdrawal). sNDA submission planned H2 2026 with potential commercial launch in 2027.
Strong Cash Generation and Balance Sheet
Ended Q1 with $178.1M cash, generated $42.4M cash from operations in Q1 (despite large incentive rebate payments), and increased cash by $33.3M in the quarter. Company executed $11.1M in share repurchases under buyback program.
Acquisition Contribution and Portfolio Expansion
Melinta acquisition (closed Aug 2025) contributed $29.9M revenue in Q1 2026 and expanded product portfolio, supporting both top-line growth and strategic pipeline diversification (including BARDA-partnered pediatric/biodefense programs).
CRMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CRMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2026 | $7.50 | $7.93 | +5.73% |
Mar 05, 2026 | $7.12 | $6.30 | -11.52% |
Nov 12, 2025 | $11.19 | $11.42 | +2.06% |
Aug 07, 2025 | $11.95 | $10.81 | -9.54% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Cormedix Inc. (CRMD) report earnings?
Cormedix Inc. (CRMD) is schdueled to report earning on Aug 06, 2026, TBA (Confirmed).
What is Cormedix Inc. (CRMD) earnings time?
Cormedix Inc. (CRMD) earnings time is at Aug 06, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CRMD EPS forecast?
CRMD EPS forecast for the fiscal quarter 2026 (Q2) is 0.24.